ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: LB17 • ACR Convergence 2025

    Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses

    Sitian Zang1, Ranran Yao1, Yan Wang1, Danxue Zhu1, Jing He1 and Zhanguo Li2, 1Peking University People's Hospital, Beijing, China (People's Republic), 2Peking Univeristy People's Hospital, Beijing, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…
  • Abstract Number: 2589 • ACR Convergence 2025

    Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome

    Yuanpiao Ni1, Fanxin Zeng2, Yufeng Qing3 and Quanbo Zhang3, 1Affiliated Hospital Of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic), 2Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic), 3The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)

    Background/Purpose: Gout is a metabolic disorder driven by abnormalities in urate metabolism and chronic inflammation. Recent studies suggest that gout is not limited to joint…
  • Abstract Number: 2335 • ACR Convergence 2025

    The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.

    Walter P. Maksymowych1, Raj Sengupta2, Anthony Marotta3, Stephanie Wichuk4, Charlotte Cavill5, Stephen Bleakley3 and Norma Biln6, 1Department of Medicine, University of Alberta, 568 Heritage Building, Edmonton, AB, Canada, 2Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, 3Augurex Life Sciences Corp, Vancouver, BC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, 6Augurex Life Sciences, Vancouver, BC, Canada

    Background/Purpose: Reducing diagnostic delay for people presenting with back pain who have axial spondyloarthritis (axSpA) has become a clinical imperative since effective treatments can limit…
  • Abstract Number: 2085 • ACR Convergence 2025

    Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)

    Dagoberto Robles1, Greg Gilles2, Nathaniel H. Christiansen3, Luke Grawer4, Karim Jayyusi4, Ali Shaikh4, Rongrong Tang5, Mihra S. Taljanovic4, Jeffrey Duryea6, Edward J. Bedrick5 and C. Kent Kwoh7, 1University of Arizona, Tucson, AZ, 2University of Arizona Arthritis Center, The University of Arizona College of Medicine, Tucson, AZ, 3University of Arizona, Stockton, NJ, 4University of Arizona, Tucson, 5The University of Arizona Arthritis Center, University of Arizona, Tucson, 6Brigham and Women’s Hospital, Boston, MA, 7The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ

    Background/Purpose: Even though knee pain is ubiquitous in knee osteoarthritis (KOA) patients, currently there are limited treatment options which are only minimally or moderately efficacious…
  • Abstract Number: 1834 • ACR Convergence 2025

    Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy

    Rodolfo Martinez-Canales1, Eva Abigaid Galindo-Calvillo2, Andres M. Ortiz-Rios2, Braulio R. Avalos-Garcia2, Lorena Perez-Barbosa2, Dionicio A. Galarza-Delgado3, Cassandra Michele Skinner-Taylor2, Mario Cesar Salinas-Carmona1 and Noe Macias-Segura1, 1Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Preeclampsia (PE) is a serious complication of pregnancy associated with significant maternal and fetal outcomes. Systemic lupus erythematosus (SLE) significantly increases the risk of…
  • Abstract Number: 1703 • ACR Convergence 2025

    Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging

    Wittaya Suwakulsiri1, Lukas Andriessen2, Coline Fournier3, Saritha Kodikara4, Amy Anderson5, Jasmine Sim5, Kim-Anh Le Cao4, Yann Abraham6, Kevin Wei7, Kenneth Baker5, Arthur Pratt8, Mihir Wechalekar9, John Isaacs10 and Ranjeny Thomas1, 1Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, 2Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, 3Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia, 4Melbourne Integrative Genomics & School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia, 5Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, 6DeepLife, Vernon, France, 7Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 8University of Newcastle, Newcastle, United Kingdom, 9Flinders Medical Centre, Adelaide, Australia, 10Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Many patients living with rheumatoid arthritis (RA) can achieve remission with modern treat-to-target disease-modifying anti-rheumatic drugs (DMARDs), albeit with the risks associated with long-term…
  • Abstract Number: 1490 • ACR Convergence 2025

    Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio

    judith hernández-Sánchez1, Beatriz Tejera Segura2, Luis Bausá Gimeno1, Doryan García Olivas1, Patricia González Terrats1, MA Acosta Mérida1, Diana Botello Corzo1, Daniel Batista perdomo1, Sergio Machin González1, F Javier Nóvoa Medina1 and Jose Angel Hernandez3, 1Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, 2Hospital Insular de Gran Canaria, Las palmas, Spain, 3Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs. Vitamin D levels have been associated with disease activity in…
  • Abstract Number: 1220 • ACR Convergence 2025

    Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases

    Wei Bian1, Jian Hao1, Na zhang1, Xiaojing Zhang1, Fumin Qi1, Yin Zhao2 and Wei Wei1, 1Tianjin Medical University General Hospital, Tianjin, China (People's Republic), 2Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)

    Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
  • Abstract Number: 0694 • ACR Convergence 2025

    Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod

    isabelle peene1, Gwenny Verstappen2, Joke Deprez3, Frans Kroese2, Suzanne Arends2, Andrew Kelly4, Lana Vandersarren5, Edward Bowen6, Julie Jacobs7, Paul Meyvisch8, Dirk Elewaut9 and Hendrika Bootsma10, 1University Hospital Ghent, Ghent, Belgium, 2University Medical Center Groningen, Groningen, Netherlands, 3Ghent University, Ghent, Belgium, 4Argenx, Philadelphia, PA, 5Argenx, Boston, MA, 6IQVIA, Stevenage, United Kingdom, 7argenx, Ravels, Belgium, 8argenx, Ghent, Belgium, 9VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, 10UMCG, Groningen, Netherlands

    Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…
  • Abstract Number: 0873 • ACR Convergence 2025

    Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

    Lihi Eder1, Shangzhong Li2, Philip J. Mease3, Christopher Ritchlin4, Walter P Maksymowych5, Hendrik Schulze-Koops6, Josef Smolen7, Oliver FitzGerald8, Vinod Chandran9, Chun Wu10 and Jinqi Liu2, 1University of Toronto, Toronto, ON, Canada, 2Bristol Myers Squibb, Princeton, NJ, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4University of Rochester Medical Center, Canandaigua, NY, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, 7Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 8UCD, Dublin 6, Dublin, Ireland, 9Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 10Bristol Myers Squibb, Princeton

    Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
  • Abstract Number: 0758 • ACR Convergence 2025

    Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis

    Raquel Ugena-García1, Clara Churtichaga Domenech2, Judith Vidal-Ripoll2, Francina salabert-Carreras2, Cristina Calomarde-Gómez1, Cristina Rocamora-Gisbert3, Irene Peralta-García4, Niccolo Viveros2, Anne Riveros Frutos3, Ivette Casafont-Solé1 and Judit Font-Urgelles1, 1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Barcelona, 3Hospital Germans Trias i Pujol, Barcelona, Spain, 4Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
  • Abstract Number: 0406 • ACR Convergence 2025

    Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis

    Ilaria Maccora1, Mariia Pavlenko2, Mekibib Altaye3, Hermine Brunner4, Margaret Chang5, Ashley Cooper6, Stefanie Davidson7, Alexandra Duell4, Bharti Gangwani5, Aimee Hersh8, Gary Holland9, Carl Langefeld10, Melissa Lerman11, Mindy Lo5, Virginia Miraldi Utz4, Sampath Prahalad12, Grant Schulert4, Megan Quinlan-Waters13, Erin Stahl6, Edmund Tsui9 and Sheila Angeles-Han14, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, 3Cincinnati Children's Hospital, Cincinnati, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Boston Children's Hospital, Boston, MA, 6Children's Mercy Kansas City, Kansas City, MO, 7Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, 8University of Utah, Salt Lake City, UT, 9UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, 10Wake Forest University School of Medicine, Winston Salem, NC, 11Children's Hospital of Philadelphia, Philadelphia, PA, 12Emory + Children's Pediatric Institute, Atlanta, GA, 13Cincinnati Children's Hospital Medical Center, CCHMC, 14Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…
  • Abstract Number: 0094 • ACR Convergence 2025

    Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs

    Sagrario Corrales1, Laura muñoz-Barrera1, Rafaela Ortega-Castro2, Elena Moreno-Caño3, Jerusalén Calvo4, Concepción Aranda-Valera4, Lourdes Ladehesa5, Pilar Font6, Ismael Sanchez-Pareja1, M Carmen Abalos-Aguilera7, Desiree Ruiz-Vilchez8, Christian Merlo9, MARIA ANGELES AGUIRRE ZAMORANO1, Tomás Cerdó1, Nuria Barbarroja10, Marta Alarcon-Riquelme11, Alejandro Escudero Contreras4, Carlos Pérez Sánchez12 and Chary López pedrera13, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 3IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 4IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 5IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 7Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 8Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 9Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 11Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 12Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 13Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain

    Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…
  • Abstract Number: 2584 • ACR Convergence 2025

    Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis

    Lea Dionet1, Federica Pallotti2, Margot Poux3, Quentin Delcros4, Nader Yatim5, Brian Soong6, Paul Breillat7, Kevin Chevalier8, claudie Cladière9, Patrick Bruneval10, Benoit Terris4, Alexis REGENT11, Xavier Puéchal12, Luc Mouthon13, Miriam Merad6, Olivia Lenoir14, Pierre-Louis Tharaux15, Maxime Samson16 and Benjamin Terrier17, 1INSERM, Paris, France, 2Internal Medicine and Clinical Immunology, Rennes, France, 3Université de Paris, PARIS 04EME, France, 4AP-HP, Paris, France, 5University of Paris-Cite, New York, NY, 6Mount Sinai School of Medicine, New York, 7INSERM, PARIS 17, Ile-de-France, France, 8Université Paris Cité, Montrouge, France, 9Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, 10AP-HP, Paris, 11Hopital Cochin, Paris, France, 12Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 13Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 14Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, Ile-de-France, France, 15Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, France, 16CHU Dijon Bourgogne, Dijon, France, 17Cochin Hospital, Paris, France

    Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting individuals over 50 years of age. Current models implicate genetic susceptibility, immune senescence, activation of…
  • Abstract Number: 2325 • ACR Convergence 2025

    Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis

    Natalia Guajardo-Jauregui1, Iris J. Colunga-Pedraza2, Dionicio A. Galarza-Delgado2, Jose R Azpiri-Lopez3, Jesus Alberto Cardenas-de la Garza4, Diana E. Flores-Alvarado5 and Rosa Arvizu-Rivera6, 1Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 5Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, 6Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico

    Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated condition associated with an increased risk of cardiovascular (CV) events due to disease-specific characteristics. Galectin-3 (Gal-3) is a…
  • 1
  • 2
  • 3
  • …
  • 109
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology